Showing results (21-30 of 56) with videos related to
Sort By:
Pageof 6
The Oncologist|December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2013
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summaryPaul G Kluetz, Yang-Min Ning, V Ellen Maher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2013
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summaryPaul G Kluetz, William Pierce, V Ellen Maher, et al.Frontiers in Neurology|April 13, 2026
Development and Validation of Quality of Life in Idiopathic Intracranial Hypertension (QOLIH) questionnaireMona Hussein, Amr Hassan, Mona A F Nada, et al.The Lancet. Oncology|December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summaryYangmin M Ning, William Pierce, V Ellen Maher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2019
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled AnalysisLynn J Howie, Harpreet Singh, Erik Bloomquist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.Pageof 6